1105710-21-1

Basic information

• Product Name: 1,1-dimethylethyl (2-bromo-1,3-thiazol-5-yl)((2S)-2-((((1,1-dimethylethyl)oxy)carbonyl)amino)-3-(4-(trifluoromethyl)phenyl)propyl)-carbamate
• Synonyms: 1,1-dimethylethyl (2-bromo-1,3-thiazol-5-yl)((2S)-2-((((1,1-dimethylethyl)oxy)carbonyl)amino)-3-(4-(trifluoromethyl)phenyl)propyl)-carbamate
• CAS NO: 1105710-21-1
• Molecular Weight: 580.466
• Mol File: 1105710-21-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 1,1-dimethylethyl (2-bromo-1,3-thiazol-5-yl)((2S)-2-((((1,1-dimethylethyl)oxy)carbonyl)amino)-3-(4-(trifluoromethyl)phenyl)propyl)-carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: 1,1-dimethylethyl (2-bromo-1,3-thiazol-5-yl)((2S)-2-((((1,1-dimethylethyl)oxy)carbonyl)amino)-3-(4-(trifluoromethyl)phenyl)propyl)-carbamate(1105710-21-1)
• EPA Substance Registry System: 1,1-dimethylethyl (2-bromo-1,3-thiazol-5-yl)((2S)-2-((((1,1-dimethylethyl)oxy)carbonyl)amino)-3-(4-(trifluoromethyl)phenyl)propyl)-carbamate(1105710-21-1)

Safety Data

• Hazardous Substances Data: 1105710-21-1(Hazardous Substances Data)

Upstream product

• 1104069-86-4 (R,S)-tert-butyl-(S)-4-(4-trifluoromethylbenzyl)-1,2,3-oxathiazolidine-3-carboxylate-2-oxide 
• 1094070-77-5 (2-bromo-thiazol-5-yl)-carbamic acid tert-butyl ester 
• 944805-79-2 tert-butyl (4S)-4-(4-(trifluoromethyl)benzyl)-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide 

Downstream Products

• 1105710-22-2 1,1-dimethylethyl ((2S)-2-((((1,1-dimethylethyl)oxy)carbonyl)amino)-3-(4-(trifluoromethyl)phenyl)propyl)(2-(6-isoquinolinyl)-1,3-thiazol-5-yl)carbamate 

Relevant articles and documents

Azole-based inhibitors of AKT/PKB for the treatment of cancer

Through a combination of screening and structure-based rational design, we have discovered a series of N1-(5-(heterocyclyl)-thiazol-2-yl)-3-(4-trifluoromethylphenyl)-1,2-propanediamines that were developed into potent ATP competitive inhibitors of AKT. Studies of linker strand-binding adenine isosteres identified SAR trends in potency and selectivity that were consistent with binding interactions observed in structures of the inhibitors bound to AKT1 and to the counter-screening target PKA. One compound was shown to have acceptable pharmacokinetic properties and to be a potent inhibitor of AKT signaling and of in vivo xenograft tumor growth in a preclinical model of glioblastoma.